Etravirine TMC-125 CAS 269055-15-4 Assay ≥99.0% (HPLC) API Factory High Purity

Short Description:

Chemical Name: Etravirine (TMC-125)  

CAS: 269055-15-4

Appearance: White Solid Powder

Assay: ≥99.0% (HPLC)

Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used for the treatment of HIV

API High Quality, Commercial Production

Inquiry: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

Description:

Manufacturer with High Purity and Stable Quality
Chemical Name: Etravirine (TMC-125)
CAS: 269055-15-4  
API High Quality, Commercial Production

Chemical Properties:

Chemical Name Etravirine
Synonyms TMC-125
CAS Number 269055-15-4
CAT Number RF-API54
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C20H15BrN6O
Molecular Weight 435.28
Density 1.439 g/cm3
Shipping Condition Under Ambient Temperature
Brand Ruifu Chemical

Specifications:

Item Specifications
Appearance White Solid Powder
Identification By IR, HPLC
Melting Point 211.0~216.0℃
Water Content ≤0.50%
Residue on Ignition ≤0.20%
Heavy Metals ≤20ppm
Any Single Impurity ≤0.50%
Total Impurities ≤1.0%
Assay ≥99.0% (HPLC)
Test Standard Enterprise Standard

Package & Storage:

Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.

Advantages:

1

FAQ:

Application:

Etravirine (TMC-125) (CAS 269055-15-4) is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) used for the treatment of HIV. It is indicated for use in combination with other antiretroviral agents for treating HIV-1 infection in treatment-experienced adult patients who have evidence of viral replication and HIV-1 strains resistant to the currently available NNRTIs and other antiretroviral agents. The NNRTIs, along with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs/NtRTIs), are important components of the combination regimens currently used to treat HIV-1 infection. The NRTIs/NtRTIs act by competing with the natural nucleotide substrates of reverse transcriptase for incorporation into viral DNA and subsequent chain termination. By contrast, the NNRTIs bind to an allosteric site of the enzyme and disrupt the DNA polymerase function by inducing conformational changes to the catalytic site. 

  • Write your message here and send it to us